All In Biotech

Drug Trial Radar · NCT02966834

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)

Last checked: Nov 20, 2026Latest source record: May 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Jan 11, 2017

Primary completion

Apr 15, 2020

Study completion Apr 15, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will receive either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram \[mg\], 90 mg or 180 mg taken once daily or 90 mg twice daily). Participants on GSK2330672 will also receive placebo tablets to maintain blinding. The study has a prospectively defined adaptive design that will utilize interim data to further inform and potentially optimize the doses under investigation. Hence, additional dose regimen may be added during study. The total duration of a participant in the study will be up to 45 days of screening and 24 weeks of study including follow-up.

Conditions

  • Cholestasis

Interventions

  • PlaceboDrug

    GSK2330672 matching placebo will be supplied as white film-coated tablets.

  • GSK2330672Drug

    GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch ScoreTime frame: Baseline and Week 16

Locations

66 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Novi, Michigan

  • GSK Investigational Site

    Manhasset, New Jersey

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Allentown, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Camperdown, New South Wales, Australia

  • GSK Investigational Site

    Herston, Queensland, Australia

  • GSK Investigational Site

    Prahran, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Winnipeg, Manitoba, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Clermont-Ferrand, France

  • GSK Investigational Site

    Grenoble, France

  • GSK Investigational Site

    Lille, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Pessac, France

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Erlangen, Bavaria, Germany

  • GSK Investigational Site

    Homburg, Saarland, Germany

  • GSK Investigational Site

    Bologna, Emilia-Romagna, Italy

  • GSK Investigational Site

    Milan, Lombardy, Italy

  • GSK Investigational Site

    Monza (MB), Lombardy, Italy

  • GSK Investigational Site

    Florence, Tuscany, Italy

  • GSK Investigational Site

    Padova, Veneto, Italy

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Fukui, Japan

  • GSK Investigational Site

    Gunma, Japan

  • GSK Investigational Site

    Hiroshima, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Kagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Nagasaki, Japan

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.